» Articles » PMID: 17364435

Excellent Inter-rater, Intra-rater, and Telephone-administered Reliability of the ALSFRS-R in a Multicenter Clinical Trial

Overview
Publisher Informa Healthcare
Specialty Neurology
Date 2007 Mar 17
PMID 17364435
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

We wished to determine whether the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) is reliable when used as primary outcome measure in a multicenter clinical trial. To establish inter-rater reliability, we randomly assigned 19 primary raters and 11 back-up raters to score nine amyotrophic lateral sclerosis (ALS) patients using the ALSFRS-R. To assess intra-rater reliability and reliability of telephone administration, we randomly assigned consecutive participants of the Clinical Trial of High Dose Coenzyme Q10 in ALS (QALS) to have in-person ALSFRS-R interviews at both screening and baseline visits (n=41 patients) or to have the ALSFRS-R interview by telephone at screening and in person at the baseline visit (n=27). An intraclass correlation coefficient (ICC) of reliability was calculated using a one-way random effects analysis of variance model. In the inter-rater reliability assessment, the primary raters performed 54 ratings on nine patients with ICC=0.93 (95% CI 0.84-0.98). For back-up raters, 32 ratings on nine patients resulted in ICC=0.93 (95% CI 0.82-0.98). The intra-rater reliability for in-person interviews was ICC = 0.95 (95% CI 0.92-0.98). The reliability of telephone administration compared to in-person interviews was ICC=0.97 (95% CI 0.93-0.98). We conclude that the ALSFRS-R shows excellent inter- and intra-rater reliability, and reliability of telephone administration when used as primary outcome measure in a multicenter ALS trial.

Citing Articles

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B JAMA Neurol. 2025; .

PMID: 40067754 PMC: 11833655. DOI: 10.1001/jamaneurol.2024.5249.


Reliability and consistency of the Japanese version of the Primary Lateral Sclerosis Functional Rating Scale.

Yanagihashi M, Hirayama T, Shibukawa M, Nagasawa J, Fujita K, Izumi Y BMC Neurol. 2024; 24(1):282.

PMID: 39138414 PMC: 11320838. DOI: 10.1186/s12883-024-03729-6.


[Telephone assistance for neurological diseases: a systematic review].

Trejo-Gabriel-Galan J, Cubo-Delgado E Rev Neurol. 2023; 77(3):67-73.

PMID: 37466132 PMC: 10662245. DOI: 10.33588/rn.7703.2022284.


Iranian clinical practice guideline for amyotrophic lateral sclerosis.

Boostani R, Olfati N, Shamshiri H, Salimi Z, Fatehi F, Hedjazi S Front Neurol. 2023; 14:1154579.

PMID: 37333000 PMC: 10272856. DOI: 10.3389/fneur.2023.1154579.


An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.

Haji S, Fujita K, Oki R, Osaki Y, Miyamoto R, Morino H JMIR Res Protoc. 2023; 12:e42032.

PMID: 36716091 PMC: 9926342. DOI: 10.2196/42032.